156 related articles for article (PubMed ID: 38241048)
1. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
[TBL] [Abstract][Full Text] [Related]
2. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Chow EJ; Aplenc R; Vrooman LM; Doody DR; Huang YV; Aggarwal S; Armenian SH; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Leisenring WM; Asselin BL; Schwartz CL; Lipshultz SE
Cancer; 2022 Feb; 128(4):788-796. PubMed ID: 34644414
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
4. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
5. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.
Chow EJ; Asselin BL; Schwartz CL; Doody DR; Leisenring WM; Aggarwal S; Baker KS; Bhatia S; Constine LS; Freyer DR; Lipshultz SE; Armenian SH
J Clin Oncol; 2015 Aug; 33(24):2639-45. PubMed ID: 26014292
[TBL] [Abstract][Full Text] [Related]
6. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials.
Zhou R; Ng A; Constine LS; Stovall M; Armstrong GT; Neglia JP; Friedman DL; Kelly K; FitzGerald TJ; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):707-11. PubMed ID: 27020112
[TBL] [Abstract][Full Text] [Related]
8. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.
Bhakta N; Liu Q; Yeo F; Baassiri M; Ehrhardt MJ; Srivastava DK; Metzger ML; Krasin MJ; Ness KK; Hudson MM; Yasui Y; Robison LL
Lancet Oncol; 2016 Sep; 17(9):1325-34. PubMed ID: 27470081
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
10. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
11. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
Schellong G; Riepenhausen M; Bruch C; Kotthoff S; Vogt J; Bölling T; Dieckmann K; Pötter R; Heinecke A; Brämswig J; Dörffel W
Pediatr Blood Cancer; 2010 Dec; 55(6):1145-52. PubMed ID: 20734400
[TBL] [Abstract][Full Text] [Related]
12. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
14. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy.
Myrehaug S; Pintilie M; Tsang R; Mackenzie R; Crump M; Chen Z; Sun A; Hodgson DC
Leuk Lymphoma; 2008 Aug; 49(8):1486-93. PubMed ID: 18608873
[TBL] [Abstract][Full Text] [Related]
15. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
16. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
[TBL] [Abstract][Full Text] [Related]
18. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort.
Mulrooney DA; Hyun G; Ness KK; Ehrhardt MJ; Yasui Y; Duprez D; Howell RM; Leisenring WM; Constine LS; Tonorezos E; Gibson TM; Robison LL; Oeffinger KC; Hudson MM; Armstrong GT
BMJ; 2020 Jan; 368():l6794. PubMed ID: 31941657
[TBL] [Abstract][Full Text] [Related]
19. Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.
Giulino-Roth L; Pei Q; Buxton A; Bush R; Wu Y; Wolden SL; Constine LS; Kelly KM; Schwartz CL; Friedman DL
Blood; 2021 Mar; 137(11):1449-1456. PubMed ID: 33512412
[TBL] [Abstract][Full Text] [Related]
20. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
